trending Market Intelligence /marketintelligence/en/news-insights/trending/Gz06MofwPQmPrJq6Vj_rcw2 content esgSubNav
In This List

US FDA grants orphan drug status to Organovo's NovoTissues for liver disease

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


US FDA grants orphan drug status to Organovo's NovoTissues for liver disease

The U.S. Food and Drug Administration granted Organovo Holdings Inc.'s 3D bioprinted liver treatment, NovoTissues, the orphan drug status.

The treatment is meant to treat the alpha-1 antitrypsin deficiency, a type of genetic disorder affecting the liver.

Organovo CEO Taylor Crouch said the company was on track for filing an investigational new drug application for the treatment in 2020 as it continues to conduct safety and dosing investigations in small animal disease models.